Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients (Q33603121)

28 July 2017

title

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients (English)

1 reference

28 July 2017

0 references

Alfredo Dragani

7

0 references

author name string

Andrea Patriarca

1

1 reference

28 July 2017

Franca Pompetti

2

1 reference

28 July 2017

Raniero Malizia

3

1 reference

28 July 2017

Ornella Iuliani

4

1 reference

28 July 2017

Ilaria Di Marzio

5

1 reference

28 July 2017

Antonio Spadano

6

1 reference

28 July 2017

publication date

1 January 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

8

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

21-27

1 reference

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

The World Health Organization (WHO) classification of the myeloid neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809508

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

30 October 2018

1 reference

12 December 2020

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

1 reference

12 December 2020

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

12 December 2020

Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia

1 reference

12 December 2020

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

1 reference

12 December 2020

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

1 reference

12 December 2020

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

1 reference

12 December 2020

Identifiers

DOI

10.2450/2009.0004-09

1 reference

28 July 2017

1 reference

28 July 2017

1 reference